Nasdaq Gives Listed Firms 180 Days to Fix Value
Companies that fall below Nasdaq's market value floors for 30 days must regain compliance within 180 days or face delisting.
Updated on Nov. 2, 2026 in Public Companies
Nasdaq sent POMDOCTOR LIMITED two deficiency letters on October 28, 2026, saying the digital healthcare company no longer meets the $50 million market value of listed securities (MVLS) and $15 million market value of publicly held shares (MVPHS) requirements. The company has until April 26, 2027 to regain compliance with both continued listing standards.
Why it matters
The deficiencies arose after both measures stayed below Nasdaq thresholds for 30 consecutive business days from September 16 through October 27, 2026. For operators, the case shows how quickly a listing can enter a compliance clock when market value falls below exchange minimums, and how the exchange's cure period works.
Two Nasdaq letters cite a $50 million MVLS floor and a $15 million MVPHS floor, each tested over 30 consecutive business days and each allowed a 180-day cure period. The filing-based evidence does not disclose the company's actual share-value figures, leaving the size of the shortfall unstated.
The players
Nasdaq Listing Qualifications Department
Nasdaq's unit that reviews listed companies for compliance with continued listing standards and issues deficiency determinations to issuers.
POMDOCTOR LIMITED
A digital healthcare company based in Guangzhou, China, whose shares trade on Nasdaq under the ticker POM.
The details
Nasdaq measured POMDOCTOR LIMITED's market value of listed securities and market value of publicly held shares across 30 consecutive business days. Because both values closed below the required minimums throughout that stretch, the exchange issued separate deficiency determinations in two letters. To regain compliance, each measure must close at or above its threshold for at least ten consecutive business days before the 180-day window closes. If the company does not cure, Nasdaq will notify it in writing that its securities are subject to delisting.
Timeline
September 16 through October 27, 2026: 30-business-day measurement period
October 28, 2026: Nasdaq issues two deficiency letters
April 26, 2027: 180-day compliance period ends for both requirements
Market Landscape
The deficiency letters apply Nasdaq Listing Rule 5450(b)(3)(A) and its companion market value of publicly held shares test to a Chinese-based issuer listed in the United States. The case follows the exchange's standard framework of a 30-business-day measurement period followed by a 180-day cure window for listed companies.
Operators who hold or issue listed securities should monitor market value against exchange floors, since a 30-day shortfall triggers a formal deficiency and a compliance clock. Finance and investor-relations teams should track the cure requirement of ten consecutive business days above threshold, and consult qualified counsel or an accountant on any response strategy.
The takeaway
A listing deficiency runs on fixed deadlines, so companies facing one should calendar the 180-day window and the ten-business-day cure threshold immediately. Operators tracking exchange compliance should watch for any written delisting notice that follows the April 2027 deadline.
What happens next
The company must regain compliance with both MVLS and MVPHS requirements by April 26, 2027, or face a written delisting notice.
Further reading
For broader context on how exchange listing rules shape public company obligations, explore our Public Companies coverage.
